Abstract: Disclosed are an underground engineering rock mass shear simulation test device, a test method and a test machine. The test method includes: setting different test conditions by a controller to perform cyclic shear test at high temperature, fracture shear seepage test, granite uniaxial compression test at high temperature and granite fracture shear test under constant normal stiffness boundary conditions at room temperature. The electric heating wire assembly, the fan assembly and the environmental box are combined to flexibly and uniformly heat the samples placed in the upper shear box and the lower shear box. In terms of shear-seepage test, this scheme proposes a second sample placing mechanism that realizes sealing through sealing capsule and sealing capsule pressing plate. It realizes stable sealing and facilitates monitoring and debugging of seepage parameters.

Abstract: A battery cell appearance defect detection apparatus may comprise: a first detection assembly comprising a first image collector and a first light source, wherein the first light source emits first light, the first light forming a first included angle with a detection surface, and the first image collector collects a first image of the position on the battery cell irradiated by the first light; a second detection assembly comprising a second image collector and a second light source, wherein the second light source emits second light, the second light forming a second included angle with the detection surface, and the second image collector collects a second image of the position on the battery cell irradiated by the second light, with the second included angle being less than the first included angle; and a control assembly constructed to detect appearance defects of the battery cell.

Abstract: The present disclosure discloses a strain of Acidomyces acidothermus and its application in leaching copper-containing pollutants from waste circuit boards, belonging to the technical field of bio-leaching. According to the present disclosure, a strain of A. acidothermus is separated from the sludge of a Changzhou sewage treatment plant; and the strain can normally grow under an acidic condition, and copper contained in a system can be leached out in a form of copper ions by adding the strain into waste or pollutants containing heavy metal copper, so that the metal copper in the waste or pollutants is effectively treated. The treatment process is simple, the requirements for the environment and the technology are low, and the treated waste liquid does not contain high-concentration chemical reagents, which facilitates subsequent waste liquid treatment; and therefore, the A. acidothermus is suitable for industrial application.

Abstract: A method for preparing a filling material includes: dissolving FeCl3·6H2O and an imprinted molecule in water to form a reaction solution; adding DMF to the reaction solution and stirring for dissolution; adding BDC to the reaction solution and stirring for dissolution; soaking PC into the reaction solution and stirring; and treating the reaction solution by a hydrothermal method to remove a molecule of an additive decomposition product and prepare the filling material imprinted with a casting structure of the molecule of additive decomposition product. The present invention can effectively and selectively adsorb the additive decomposition products and achieve the effects of effectively removing the additive decomposition products, preventing the decomposition products from being mixed in an electrodeposition film of the copper, realizing the uniform distribution of current on the cathode and the anode, improving the quality and preparing an electrolytic copper foil for high-frequency signal transmission.

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent antitumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent antitumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

Abstract: An oncolytic adenovirus vector and its potential application in cancer treatment and vaccination. The inventive vector (named Ad-TD-hIL12) is derived from the human adenovirus group C type 5, more particularly including deletion of three adenovirus genes E1A-CR2, E1B19K and E3gp-19K, and a fused cDNA sequence of p35 and p40 subunit of human IL12 placed under the control of the E3gp-19K promoter. The invention also includes a method to construct the triple gene-deleted vector (Ad-TD). The Ad-TD-hIL12 and Ad-TD-shIL12 (with a short p40 sequence of human IL 12) vectors can be used as targeted, genetically engineered agents for treatment of various solid tumors, via not only intratumoral injection, and also in intraperitoneal injection, without causing significant side effects, showing a superior antitumor efficacy and safety.

Abstract: The present invention discloses a method of multi-active detection and a stack member device. Each member device in a stack is configured with a detection interface that is assigned an IP address, wherein the IP address of the detection interface on the designated active device is activated. Each member devices is also configured with an active device election rule, and with a correspondence between the IP address of the detection interface on each member device and the active device election parameter of the member device. Upon detection that the stack has become split, each designated standby device transitions to become an active device and activates the IP address of its detection interface.